Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  12,101 results for ""Acrylamides""

Your Filters

Filter by : Subject
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages.

  • Authors : Lin TT; Department of Pharmacy, Binzhou Medical University Hospital, Binzhou, 256603, China.; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.

Subjects: Acrylamides*/Acrylamides*/Acrylamides*/pharmacology ; Acrylamides*/Acrylamides*/Acrylamides*/therapeutic use ; Aniline Compounds*/Aniline Compounds*/Aniline Compounds*/pharmacology

  • Source: Acta pharmacologica Sinica [Acta Pharmacol Sin] 2024 Apr; Vol. 45 (4), pp. 867-878. Date of Electronic Publication: 2023 Dec 19.Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 100956087 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Sialyltransferase ST3GAL4 confers osimertinib resistance and offers strategies to overcome resistance in non-small cell lung cancer.

  • Authors : Han R; Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.; Lin C

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/genetics ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/drug therapy

  • Source: Cancer letters [Cancer Lett] 2024 Apr 28; Vol. 588, pp. 216762. Date of Electronic Publication: 2024 Feb 24.Publisher: Elsevier Science Ireland Country of Publication: Ireland NLM ID: 7600053 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR -Mutant Non-Small-Cell Lung Cancer.

  • Authors : Remon J; Paris-Saclay University, Institut Gustave Roussy, Villejuif, France.; Besse B

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/drug therapy ; Acrylamides*

  • Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Apr 20; Vol. 42 (12), pp. 1350-1356. Date of Electronic Publication: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.

  • Authors : Li X; Department of Research and Development, Duality Biologics, LTD, Unite 1106 868 Yinghua Road, Shanghai, 201204, P.R. China. .; Yao J

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/pathology ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/drug therapy ; Immunoconjugates*/Immunoconjugates*/Immunoconjugates*/pharmacology

  • Source: Journal of translational medicine [J Transl Med] 2024 Apr 17; Vol. 22 (1), pp. 362. Date of Electronic Publication: 2024 Apr 17.Publisher: BioMed Central Country of Publication: England NLM ID: 101190741 Publication Model: Electronic Cited Medium: Internet ISSN: 1479-5876

Record details

Read More Add to Saved list
×
Academic Journal

A Path to Persistence after EGFR Inhibition.

  • Authors : Rumde PH; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania.; Burns TF

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/genetics ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/drug therapy

  • Source: Cancer research [Cancer Res] 2024 Apr 15; Vol. 84 (8), pp. 1188-1190.Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients.

  • Authors : Zhao J; Laboratory of Clinical Pharmacokinetics, Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201213, China.; Yan D

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use ; Neoplasms*/Neoplasms*/Neoplasms*/drug therapy ; Quinolines*

  • Source: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences [J Chromatogr B Analyt Technol Biomed Life Sci] 2024 Apr 15; Vol. 1237, pp. 124100. Date of Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101139554 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.

  • Authors : Hu B; Department of Pathology, Yale School of Medicine, New Haven, Connecticut.; Wiesehöfer M

Subjects: Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/drug therapy ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/genetics ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/pathology

  • Source: Cancer research [Cancer Res] 2024 Apr 15; Vol. 84 (8), pp. 1303-1319.Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC.

  • Authors : Lee EJ; Department of Biomedical Science institute, Graduated School of Medical Science, Brain Korea 21 FOUR Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.; Oh SY

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/genetics ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/pathology

  • Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Apr 15; Vol. 30 (8), pp. 1582-1594.Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265

Record details

Read More Add to Saved list
×
Academic Journal

EGFR degraders in non-small-cell lung cancer: Breakthrough and unresolved issue.

  • Authors : Shen J; Key Laboratory of Organo-Pharmaceutical Chemistry of Jiangxi Province, Gannan Normal University, Ganzhou, Jiangxi, China.; Chen L

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/genetics ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/drug therapy

  • Source: Chemical biology & drug design [Chem Biol Drug Des] 2024 Apr; Vol. 103 (4), pp. e14517.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101262549 Publication Model: Print Cited Medium: Internet ISSN: 1747-0285

Record details

Read More Add to Saved list
×
Academic Journal

CNS Antitumor Activity of Amivantamab With Osimertinib in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer With Acquired Mesenchymal-Epithelial Transition Amplification Resistance Mechanism: A Case Report.

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/genetics ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/pathology

  • Source: JCO precision oncology [JCO Precis Oncol] 2024 Apr; Vol. 8, pp. e2300677.Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet

Record details

Read More Add to Saved list
×
  • 1-10 of  12,101 results for ""Acrylamides""